Skip to main content

Table 2 Efficacy results at week 26 (FAS, LOCF)

From: Efficacy and safety of rasagiline in Chinese patients with early Parkinson’s disease: a randomized, double-blind, parallel, placebo-controlled, fixed-dose study

Efficacy parameter Change from baseline Difference vs. placebo (95% CI) P value
Placebo (n = 63) Rasagiline 1 mg (n = 64)
Primary efficacy
 UPDRS total score -0.18 ± 0.98 −3.18 ± 0.95 − 3.00 (− 5.62 to − 0.38) 0.025
Secondary efficacy
 UPDRS part I 0.08 ± 0.15 − 0.54 ± 0.15 −0.62 (− 1.03 to − 0.21) 0.003
 UPDRS part II 0.25 ± 0.38 −0.43 ± 0.37 −0.67 (− 1.70 to 0.35) 0.196
 UPDRS part III −0.52 ± 0.68 − 2.23 ± 0.65 − 1.71 (− 3.52 to 0.10) 0.064
Exploratory efficacy
 Percent respondersa 42 (66.7) 51 (79.7)   0.051
 Odds ratio (95% CI) 2.55 (1.00 to 6.54)    
 CGI-S score 0.08 ± 0.08 0.04 ± 0.08 −0.04 (− 0.25 to 0.17) 0.699
 CGI-I score 3.88 ± 0.11 3.68 ± 0.11 − 0.20 (− 0.50 to 0.10) 0.196
  1. Data are mean ± standard error of the mean or n (%).
  2. a Responders with worsening of < 3 points in UPDRS total score. CGI-I, Clinical Global Impressions Scale-Improvement; CGI-S, Clinical Global Impressions Scale-Severity; CI, confidence interval; UPDRS, Unified Parkinson’s Disease Rating Scale